Register to chat with like-minded investors on our interactive forums.
The current GNNSF market cap is 3.78B. The company's latest EPS is USD 1.3945 and P/E is 1.28.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 390.85M | 490.1M | 625.7M | 839.53M | 1.04B |
| Operating Income | -196.32M | -371.01M | -447.32M | -401.5M | -200.71M |
| Net Income | -204.95M | -358.71M | -226.85M | -95.48M | 2.96B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.45B | 2.23B | 2.55B | 3.39B | 5.28B |
| Total Liabilities | 631.82M | 846.18M | 1.18B | 1.34B | 954.91M |
| Total Equity | 815.59M | 1.39B | 1.36B | 2.04B | 4.32B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -151.09M | -136.79M | -120.29M | -286.91M | 75.65M |
| Investing | -100.17M | -212.55M | -443.3M | -357.73M | -1.46B |
| Financing | 624.2M | 902.14M | 419.32M | 1.07B | 66.52M |
| Market Cap | 3.78B |
| Price to Earnings Ratio | 1.28 |
| Price to Sales Ratio | 3.65 |
| Price to Cash Ratio | 9.54 |
| Price to Book Ratio | 0.87 |
| Dividend Yield | - |
| Shares Outstanding | 2.12B |
| Average Volume (1 week) | 125 |
| Average Volume (1 Month) | 1.27k |
| 52 Week Change | 16.34% |
| 52 Week High | 1.90 |
| 52 Week Low | 1.05 |
| Spread (Intraday) | 0.54 (30%) |
| Company Name | Genscript Biotech Corporation (PK) |
| Address |
4th floor, harbour place grand cayman KY1-1002 |
| Website | https://www.genscript.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
